| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.25 | 1e-15 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.41 | 1e-14 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.31 | 1e-14 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.42 | 2e-14 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | 0.27 | 3e-12 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | 0.24 | 6e-11 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-10 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.27 | 3e-10 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.24 | 5e-10 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-09 |